Robbert J. de Winter
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Robbert J. de Winter has a total of 214 co-authors. Here are the top co-authors by number of shared publications:
- Joanna J. Wykrzykowska
Department of Cardiology, Groningen UMC, Groningen, The Netherlands
7 shared publications - Patrick W. Serruys
University of Galway
7 shared publications - Yoshinobu Onuma
Department of Cardiology, University of Galway, Galway, Ireland; CORRIB Research Centre for Advanced Imaging and Core Lab, University of Galway, Galway, Ireland
6 shared publications - Jose Paulo Simao Henriques
Department of Cardiology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands
5 shared publications - Jan J. Piek
Department of Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
4 shared publications - Marcel A. M. Beijk
Department of Cardiology Amsterdam University Medical Center Amsterdam the Netherlands
4 shared publications
Latest Publications
- Open Access
- 30 January 2024
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 8 (2) , ytae043
Severe silent ischaemia detected with an Apple Watch in the home setting: a case report
Background: The Apple Watch has the capability to record a lead 1 electrocardiogram (ECG) and can identify and report atrial fibrillation. The use for detecting myocardial ischaemia is not endorsed by Apple but is documented in this case. Case summary: A 76-year-old man made a lead 1 ECG with his Apple Watch immediately after exercising on a cross trainer. He was fully asymptomatic. The ECG showed an unusual negative T-wave in this lead 1 that deepened in a few minutes and returned to normal after 22 min. He consulted a cardiologist and a standard exercise ECG confirmed the negative T-wave in lead 1 after maximal exercise and in addition showed widespread ST-depression indicating myocardial ischaemia, again without any clinical symptoms. Further studies revealed severe obstructive three-vessel coronary artery disease that was considered not suitable for percutaneous intervention. A coronary artery bypass operation on all involved vessels was performed successfully. Recovery was uneventful and an exercise ECG repeated 11 weeks later was normal. Discussion: We demonstrated that the lead 1 ECG made with the Apple Watch can reliably record T-wave changes indicating myocardial ischaemia. The use of the Apple Watch to document ischaemic changes should be studied systematically for its potential to identify myocardial ischaemia, mainly triggered by symptoms but maybe for asymptomatic persons as well.
- 30 January 2024
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 8 (2) , ytae043
Open AccessSevere silent ischaemia detected with an Apple Watch in the home setting: a case report
Background: The Apple Watch has the capability to record a lead 1 electrocardiogram (ECG) and can identify and report atrial fibrillation. The use for detecting myocardial ischaemia is not endorsed by Apple but is documented in this case. Case summary: A 76-year-old man made a lead 1 ECG with his Apple Watch immediately after exercising on a cross trainer. He was fully asymptomatic. The ECG showed an unusual negative T-wave in this lead 1 that deepened in a few minutes and returned to normal after 22 min. He consulted a cardiologist and a standard exercise ECG confirmed the negative T-wave in lead 1 after maximal exercise and in addition showed widespread ST-depression indicating myocardial ischaemia, again without any clinical symptoms. Further studies revealed severe obstructive three-vessel coronary artery disease that was considered not suitable for percutaneous intervention. A coronary artery bypass operation on all involved vessels was performed successfully. Recovery was uneventful and an exercise ECG repeated 11 weeks later was normal. Discussion: We demonstrated that the lead 1 ECG made with the Apple Watch can reliably record T-wave changes indicating myocardial ischaemia. The use of the Apple Watch to document ischaemic changes should be studied systematically for its potential to identify myocardial ischaemia, mainly triggered by symptoms but maybe for asymptomatic persons as well.
- Open Access
- 1 December 2021
- Published by Europa Digital & Publishing in EuroIntervention
- Vol. 17 (12) , e1009-e1018
Chronic haemodynamic performance of a biorestorative transcatheter heart valve in an ovine model
The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)
- 1 December 2021
- Published by Europa Digital & Publishing in EuroIntervention
- Vol. 17 (12) , e1009-e1018
Open AccessChronic haemodynamic performance of a biorestorative transcatheter heart valve in an ovine model
The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)
- 1 October 2021
- Published by HMP Communications, LLC in Journal of Invasive Cardiology
- Vol. 33 (10) , E823-E832
The Impact of Percutaneous Coronary Intervention on Mortality in Patients With Coronary Lesions Who Underwent Transcatheter Aortic Valve Replacement
An institutional TAVR database was complemented with data on the extent of coronary artery disease (CAD), lesion location, lesion severity, and the location of PCI. Original Contribution from Journal of Invasive Cardiology. Coronary artery disease percutaneous coronary intervention Transcatheter aortic valve replacement
- 1 October 2021
- Published by HMP Communications, LLC in Journal of Invasive Cardiology
- Vol. 33 (10) , E823-E832
The Impact of Percutaneous Coronary Intervention on Mortality in Patients With Coronary Lesions Who Underwent Transcatheter Aortic Valve Replacement
An institutional TAVR database was complemented with data on the extent of coronary artery disease (CAD), lesion location, lesion severity, and the location of PCI. Original Contribution from Journal of Invasive Cardiology. Coronary artery disease percutaneous coronary intervention Transcatheter aortic valve replacement
- Open Access
- 1 December 2020
- Published by Elsevier in IJC Heart & Vasculature
- Vol. 31, 100605
1-Year COMBO stent outcomes stratified by the PARIS bleeding prediction score: From the MASCOT registry
- 1 December 2020
- Published by Elsevier in IJC Heart & Vasculature
- Vol. 31, 100605
Open Access1-Year COMBO stent outcomes stratified by the PARIS bleeding prediction score: From the MASCOT registry
- Open Access
- 30 November 2020
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 29 (2) , 312-320
Ten-year all-cause mortality according to smoking status in patients with severe coronary artery disease undergoing surgical or percutaneous revascularization
To evaluate the impact of various smoking status on 10-year all-cause mortality and to examine a relative treatment benefit of coronary artery bypass grafting (CABG) vs. percutaneous coronary intervention (PCI) according to smoking habits. The SYNTAX Extended Survival study evaluated vital status up to 10 years in 1800 patients with de novo three-vessel disease and/or left main coronary artery disease randomized to CABG or PCI in the SYNTAX trial. In the present analysis, patients were divided into three groups (current, former, or never smokers), and the primary endpoint of 10-year all-cause mortality was assessed according to smoking status. Smoking status was available in 1793 (99.6%) patients at the time of randomization, of whom 363 were current smokers, 798 were former smokers, and 632 were never smokers. The crude rates of 10-year all-cause mortality were 29.7% in current smokers, 25.3% in former smokers, and 25.9% in never smokers (Log-rank P = 0.343). After adjustment for imbalances in baseline characteristics, current smokers had a significantly higher risk of 10-year all-cause mortality than never smokers [adjusted hazard ratio (aHR): 2.29; 95% confidence interval (CI): 1.60–3.27; P < 0.001], whereas former smokers did not. PCI was associated with a higher risk of all-cause mortality than CABG among current smokers (HR: 1.60; 95% CI: 1.09–2.35; P = 0.017), but it failed to show a significant interaction between revascularization strategies and smoking status (Pinteraction = 0.910). Current smokers had a higher adjusted risk of 10-year all-cause mortality, whereas former smokers did not. The treatment effect of CABG vs. PCI did not differ significantly according to smoking status. SYNTAX: ClinicalTrials.gov reference: NCT00114972; SYNTAX Extended Survival. ClinicalTrials.gov reference: NCT03417050.
- 30 November 2020
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 29 (2) , 312-320
Open AccessTen-year all-cause mortality according to smoking status in patients with severe coronary artery disease undergoing surgical or percutaneous revascularization
To evaluate the impact of various smoking status on 10-year all-cause mortality and to examine a relative treatment benefit of coronary artery bypass grafting (CABG) vs. percutaneous coronary intervention (PCI) according to smoking habits. The SYNTAX Extended Survival study evaluated vital status up to 10 years in 1800 patients with de novo three-vessel disease and/or left main coronary artery disease randomized to CABG or PCI in the SYNTAX trial. In the present analysis, patients were divided into three groups (current, former, or never smokers), and the primary endpoint of 10-year all-cause mortality was assessed according to smoking status. Smoking status was available in 1793 (99.6%) patients at the time of randomization, of whom 363 were current smokers, 798 were former smokers, and 632 were never smokers. The crude rates of 10-year all-cause mortality were 29.7% in current smokers, 25.3% in former smokers, and 25.9% in never smokers (Log-rank P = 0.343). After adjustment for imbalances in baseline characteristics, current smokers had a significantly higher risk of 10-year all-cause mortality than never smokers [adjusted hazard ratio (aHR): 2.29; 95% confidence interval (CI): 1.60–3.27; P < 0.001], whereas former smokers did not. PCI was associated with a higher risk of all-cause mortality than CABG among current smokers (HR: 1.60; 95% CI: 1.09–2.35; P = 0.017), but it failed to show a significant interaction between revascularization strategies and smoking status (Pinteraction = 0.910). Current smokers had a higher adjusted risk of 10-year all-cause mortality, whereas former smokers did not. The treatment effect of CABG vs. PCI did not differ significantly according to smoking status. SYNTAX: ClinicalTrials.gov reference: NCT00114972; SYNTAX Extended Survival. ClinicalTrials.gov reference: NCT03417050.
- Open Access
- 1 January 2020
- Published by Elsevier in SSRN Electronic Journal
Four-Year Follow-Up of Absorb BVS Compared to Xience EES in Daily Clinical Practice Shows Continued Accrual of Events
Background: Absorb bioresorbable vascular scaffold (BVS) related events have been reported between 1 and 3 years – the period of active scaffold bioresorption. Data on the performance of Absorb BVS in daily clinical practice beyond this time point is scarce. We sought to assess clinical outcomes after Absorb BVS in comparison with Xience everolimus-eluting stent (EES) through 4 years and between 3 and 4 years. In addition, we evaluated the effect of prolonged DAPT in the Absorb BVS arm. Methods: AIDA was a single-blind, multicentre, investigator-initiated, non-inferiority trial, in which 1,845 unselected patients were randomly assigned to either Absorb BVS (924) or Xience EES (921). The primary endpoint was target-vessel failure, a composite of cardiac death, target-vessel myocardial infarction (TV-MI) or target-vessel revascularisation (TVR). This report provides the four-year clinical follow-up. Furthermore, we paired all scaffold thrombosis within the first 3-years to evaluate the effect of DAPT.Findings: Target-vessel failure increased from three to four years with 2.9% for Absorb BVS and 1.6% for Xience EES to a total of 16.1% versus 13.5%, respectively (p=0.078 and p=0.127). Absorb BVS is associated with higher rates of TV-MI and TVR at four-years, mainly due to device thrombosis related events. Between three and four years definite device thrombosis occurred in 0.6% of Absorb BVS versus 0.2% of Xience EES (p=0.250) with a total 4-year rate of 3.9% versus 0.8%, respectively (p<0.001). The odds ratio of scaffold thrombosis in patients off DAPT compared to on DAPT was 3.23 (95%CI 1.27-8.20).Interpretation: The excessive risk of Absorb BVS on late adverse events, in particular device thrombosis, in routine PCI continues up to 4-years. DAPT seems to be effective in lowering the risk of scaffold thrombosis. Longer follow-up is needed to investigate whether the excessive risk of Absorb BVS subsides.Funding Statement: The AIDA trial was supported by an unrestricted educational grant from Abbott Vascular. Declaration of Interests: The Amsterdam UMC Heart Center received an unrestricted educational research grant from Abbott Vascular for the AIDA trial. The Research Department of the cardiology division of the Medical Center Leeuwarden received non-study related unrestricted educational research grants from Abbott Vascular. J. Piek is a member of the Medical Advisory Board of Abbott Vascular. MedStar Washington Hospital Center receives research grants for clinical research from Abbott Vascular. J. Tijssen served on the DSMB of the early ABSROBS trial, including ABSORB II. J. Henriques received research grants from Abbott Vascular. J. Wykrzykowska received consultancy fees and research grants from Abbott Vascular. The other authors have no conflicts of interest to declare. Ethics Approval Statement: The study design was in concordance with the provisions of the Declaration of Helsinki. The research ethics committee of Academic Medical Centre, Amsterdam approved the study protocol for all participating centres. All enrolled patients provided written informed consent.
- 1 January 2020
- Published by Elsevier in SSRN Electronic Journal
Open AccessFour-Year Follow-Up of Absorb BVS Compared to Xience EES in Daily Clinical Practice Shows Continued Accrual of Events
Background: Absorb bioresorbable vascular scaffold (BVS) related events have been reported between 1 and 3 years – the period of active scaffold bioresorption. Data on the performance of Absorb BVS in daily clinical practice beyond this time point is scarce. We sought to assess clinical outcomes after Absorb BVS in comparison with Xience everolimus-eluting stent (EES) through 4 years and between 3 and 4 years. In addition, we evaluated the effect of prolonged DAPT in the Absorb BVS arm. Methods: AIDA was a single-blind, multicentre, investigator-initiated, non-inferiority trial, in which 1,845 unselected patients were randomly assigned to either Absorb BVS (924) or Xience EES (921). The primary endpoint was target-vessel failure, a composite of cardiac death, target-vessel myocardial infarction (TV-MI) or target-vessel revascularisation (TVR). This report provides the four-year clinical follow-up. Furthermore, we paired all scaffold thrombosis within the first 3-years to evaluate the effect of DAPT.Findings: Target-vessel failure increased from three to four years with 2.9% for Absorb BVS and 1.6% for Xience EES to a total of 16.1% versus 13.5%, respectively (p=0.078 and p=0.127). Absorb BVS is associated with higher rates of TV-MI and TVR at four-years, mainly due to device thrombosis related events. Between three and four years definite device thrombosis occurred in 0.6% of Absorb BVS versus 0.2% of Xience EES (p=0.250) with a total 4-year rate of 3.9% versus 0.8%, respectively (p<0.001). The odds ratio of scaffold thrombosis in patients off DAPT compared to on DAPT was 3.23 (95%CI 1.27-8.20).Interpretation: The excessive risk of Absorb BVS on late adverse events, in particular device thrombosis, in routine PCI continues up to 4-years. DAPT seems to be effective in lowering the risk of scaffold thrombosis. Longer follow-up is needed to investigate whether the excessive risk of Absorb BVS subsides.Funding Statement: The AIDA trial was supported by an unrestricted educational grant from Abbott Vascular. Declaration of Interests: The Amsterdam UMC Heart Center received an unrestricted educational research grant from Abbott Vascular for the AIDA trial. The Research Department of the cardiology division of the Medical Center Leeuwarden received non-study related unrestricted educational research grants from Abbott Vascular. J. Piek is a member of the Medical Advisory Board of Abbott Vascular. MedStar Washington Hospital Center receives research grants for clinical research from Abbott Vascular. J. Tijssen served on the DSMB of the early ABSROBS trial, including ABSORB II. J. Henriques received research grants from Abbott Vascular. J. Wykrzykowska received consultancy fees and research grants from Abbott Vascular. The other authors have no conflicts of interest to declare. Ethics Approval Statement: The study design was in concordance with the provisions of the Declaration of Helsinki. The research ethics committee of Academic Medical Centre, Amsterdam approved the study protocol for all participating centres. All enrolled patients provided written informed consent.
- 9 August 2019
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 40 (31) , 2595-2604
Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the Global Leaders trial
Aims : To evaluate the impact of an experimental strategy [23-month ticagrelor monotherapy following 1-month dual antiplatelet therapy (DAPT)] vs. a reference regimen (12-month aspirin monotherapy following 12-month DAPT) after complex percutaneous coronary intervention (PCI). Methods and results: In the present post hoc analysis of the Global Leaders trial, the primary endpoint [composite of all-cause death or new Q-wave myocardial infarction (MI)] at 2 years was assessed in patients with complex PCI, which includes at least one of the following characteristics: multivessel PCI, ≥3 stents implanted, ≥3 lesions treated, bifurcation PCI with ≥2 stents, or total stent length >60 mm. In addition, patient-oriented composite endpoint (POCE) (composite of all-cause death, any stroke, any MI, or any revascularization) and net adverse clinical events (NACE) [composite of POCE or Bleeding Academic Research Consortium (BARC) Type 3 or 5 bleeding] were explored. Among 15 450 patients included in this analysis, 4570 who underwent complex PCI had a higher risk of ischaemic and bleeding events. In patients with complex PCI, the experimental strategy significantly reduced risks of the primary endpoint [hazard ratio (HR): 0.64, 95% confidence interval (CI): 0.48–0.85] and POCE (HR: 0.80, 95% CI: 0.69–0.93), but not in those with non-complex PCI (P interaction = 0.015 and 0.017, respectively). The risk of BARC Type 3 or 5 bleeding was comparable (HR: 0.97, 95% CI: 0.67–1.40), resulting in a significant risk reduction in NACE (HR: 0.80, 95% CI: 0.69–0.92; P interaction = 0.011). Conclusion : Ticagrelor monotherapy following 1-month DAPT could provide a net clinical benefit for patients with complex PCI. However, in view of the overall neutral results of the trial, these findings of a post hoc analysis should be considered as hypothesis generating.
- 9 August 2019
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 40 (31) , 2595-2604
Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the Global Leaders trial
Aims : To evaluate the impact of an experimental strategy [23-month ticagrelor monotherapy following 1-month dual antiplatelet therapy (DAPT)] vs. a reference regimen (12-month aspirin monotherapy following 12-month DAPT) after complex percutaneous coronary intervention (PCI). Methods and results: In the present post hoc analysis of the Global Leaders trial, the primary endpoint [composite of all-cause death or new Q-wave myocardial infarction (MI)] at 2 years was assessed in patients with complex PCI, which includes at least one of the following characteristics: multivessel PCI, ≥3 stents implanted, ≥3 lesions treated, bifurcation PCI with ≥2 stents, or total stent length >60 mm. In addition, patient-oriented composite endpoint (POCE) (composite of all-cause death, any stroke, any MI, or any revascularization) and net adverse clinical events (NACE) [composite of POCE or Bleeding Academic Research Consortium (BARC) Type 3 or 5 bleeding] were explored. Among 15 450 patients included in this analysis, 4570 who underwent complex PCI had a higher risk of ischaemic and bleeding events. In patients with complex PCI, the experimental strategy significantly reduced risks of the primary endpoint [hazard ratio (HR): 0.64, 95% confidence interval (CI): 0.48–0.85] and POCE (HR: 0.80, 95% CI: 0.69–0.93), but not in those with non-complex PCI (P interaction = 0.015 and 0.017, respectively). The risk of BARC Type 3 or 5 bleeding was comparable (HR: 0.97, 95% CI: 0.67–1.40), resulting in a significant risk reduction in NACE (HR: 0.80, 95% CI: 0.69–0.92; P interaction = 0.011). Conclusion : Ticagrelor monotherapy following 1-month DAPT could provide a net clinical benefit for patients with complex PCI. However, in view of the overall neutral results of the trial, these findings of a post hoc analysis should be considered as hypothesis generating.
- 1 August 2019
- Published by Europa Digital & Publishing in EuroIntervention
- Vol. 15 (5) , 420-426
Quantitative aortography for assessing aortic regurgitation after transcatheter aortic valve implantation: results of the multicentre ASSESS-REGURGE Registry
The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)
- 1 August 2019
- Published by Europa Digital & Publishing in EuroIntervention
- Vol. 15 (5) , 420-426
Quantitative aortography for assessing aortic regurgitation after transcatheter aortic valve implantation: results of the multicentre ASSESS-REGURGE Registry
The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)
- 1 August 2018
- Published by Europa Digital & Publishing in EuroIntervention
- Vol. 14 (6) , 678-685
Quality difference of neointima following the implantation of everolimus-eluting bioresorbable scaffolds and metallic stents in patients with ST-elevation myocardial infarction: quantitative assessments by light intensity, light attenuation, and backscatter on optical coherence tomography in the TROFI II trial
The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)
- 1 August 2018
- Published by Europa Digital & Publishing in EuroIntervention
- Vol. 14 (6) , 678-685
Quality difference of neointima following the implantation of everolimus-eluting bioresorbable scaffolds and metallic stents in patients with ST-elevation myocardial infarction: quantitative assessments by light intensity, light attenuation, and backscatter on optical coherence tomography in the TROFI II trial
The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)
- 1 March 2018
- Published by Wolters Kluwer Health in Coronary Artery Disease
- Vol. 29 (2) , 171-173
Recurrent myocardial infarction in an aneurysmal coronary artery managed with stent grafts
- 1 March 2018
- Published by Wolters Kluwer Health in Coronary Artery Disease
- Vol. 29 (2) , 171-173
Recurrent myocardial infarction in an aneurysmal coronary artery managed with stent grafts